Tandem Diabetes Care, Inc. (TNDM)

In November 2025, Tandem Diabetes Care reported its last earnings, with an EPS of $-0.31, meeting estimates, but revenue of $249 million missed the estimated $277 million. In February 2026, the stock saw a significant rise, with shares increasing by 33% following an earnings beat, margin expansion, and a positive growth outlook. The company's Q4 2025 results beat Wall Street's revenue expectations, with sales up 15% year-on-year to $290.4 million, and a GAAP loss of $0.01 per share. Tandem's stock price as of March 19, 2026, was $24.63, representing an increase of 19.27% from March 20, 2025. Over the last 12 months, the stock price rose by 8.92%. Analysts have also increased price targets for TNDM.

Demand for Tandem Diabetes Care's products and services typically exhibits seasonality, with the back end of the year generally favoring the company.

Tandem Diabetes Care, Inc. is an American medical device manufacturer specializing in insulin delivery and diabetes technology, operating within the healthcare technology sector. The company's major products include the t:slim X2 insulin pump featuring Control-IQ and Basal-IQ technologies, the Tandem Mobi system with Control-IQ+ technology, Control-IQ and Basal-IQ technologies, consumables like insulin cartridges and infusion sets, the Tandem Source data management platform, and services such as diabetes education and pump training.

Tandem Diabetes Care is headquartered in San Diego, California, and operates directly in the United States, Canada, Switzerland, and the Netherlands. It has expanded its distribution through commercial partnerships in various international markets, including Australia, Germany, Portugal, the Bahamas, Ireland, Saudi Arabia, Belgium, Israel, Slovakia, Italy, South Africa, the Czech Republic, Luxembourg, Spain, Denmark, New Zealand, Norway, Finland, France, and the United Kingdom.

Tandem Diabetes Care's brand reputation is influenced by its focus on innovation and product development, including the t:slim X2 insulin pump and the Tandem Mobi system, both featuring Control-IQ technology. Recent developments, such as the FDA clearance for Control-IQ+ for type 2 diabetes and advancements in tubeless technology, have broadened its market appeal. The company's efforts to expand its CGM integration partnerships to include both Dexcom and Abbott sensors also contribute positively to its reputation. While no specific negative events severely impacted its brand reputation were highlighted, the company operates in a competitive landscape, and maintaining market share, particularly in the U.S., is an ongoing challenge.

The ownership of Tandem Diabetes Care, Inc. is predominantly held by institutional investors, who collectively held approximately 53.75% of the company's outstanding shares as of March 31, 2025. Insiders hold a smaller portion, around 0.78% to 1.90%, while public companies and individual investors account for the remaining shares. Major institutional owners include BlackRock, Inc., The Vanguard Group, Inc., Sessa Capital IM, L.P., ArrowMark Colorado Holdings LLC, UBS Group AG, GW&K Investment Management, LLC, State Street Corp, Citadel Advisors Llc and Morgan Stanley.